Evidence map›Paper›PMID 19812355›Full record

ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2009

The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6.

LaShon C Sturgis, Joseph G Cannon, Derek A Schreihofer, Michael W Brands

Abstract read
In one paragraph

Article in American journal of physiology. Regulatory, integrative and comparative physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Targeting inerleukin-6 for renoprotection.Frontiers in immunology · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Endothelial Dysfunction in Primary Aldosteronism.International journal of molecular sciences · 2019
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Role of the Immune System in Hypertension.Physiological reviews · 2017
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Vascular inflammatory cells in hypertension.Frontiers in physiology · 2012
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

LaShon C SturgisDepartment of Physiology, Medical College of Georgia, Augusta, Georgia 30912-3000, USA.
Joseph G Cannon
Derek A Schreihofer
Michael W Brands
Augusta University · US

Funding

Vascular Rho-kinase Signaling in Angiotensin II hypertenP01HL074167 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BRANDS, MICHAEL W. · 2004 to 2008
$10.5M
Mechanisms for Cardiovascular Control Early in DiabetesR01HL056259 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BRANDS, MICHAEL W. · 2003 to 2016
$4.4M
Renal Control of Blood Pressure in Early DiabetesR01HL075625 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BRANDS, MICHAEL W · 2004 to 2007
$1.1M
CARDIOVASCULAR AND RENAL DYSFUNCTION IN EARLY DIABETESR29HL056259 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI BRANDS, MICHAEL W · 1997 to 2000
$100k
NHLBI NIH HHS HL56259NHLBI NIH HHS HL74167NHLBI NIH HHS HL75625NHLBI NIH HHS P01 HL074167
6 · The paper itself

Abstract

Knockout (KO) of IL-6 has been shown to attenuate ANG II hypertension, and mineralocorticoid receptors (MR) have been reported to contribute to the increase in IL-6 during acute ANG II infusion. This study determined whether that MR action is sustained with chronic ANG II infusion and whether it plays a role in mediating ANG II hypertension. ANG II infusion (90 ng/min) increased plasma IL-6 from 1.6 +/- 0.6 to 22.7 +/- 2.2 and 19.9 +/- 3.2 pg/ml on days 7 and 14, respectively, and chronic MR blockade with spironolactone attenuated that only at day 7 (7.2 +/- 2.2 pg/ml). ANG II increased MAP (19 h/day with telemetry) approximately 40 mmHg, but in ANG II+spironolactone mice (25 or 50 mg*kg(-1)*day(-1)), mean arterial pressure (MAP) was not significantly different despite a tendency for lower pressure the first 6 days. To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice. Plasma IL-6 increased from 4.1 +/- 1.7 to 34.5 +/- 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14. An IL-6 bioassay using the murine B9, B-cell hybridoma cell line demonstrated that plasma IL-6 measurements reflected actual IL-6 bioactivity. The hypertension was not different and virtually superimposable in WT vs. IL-6 KO mice, averaging 145 +/- 2 and 144 +/- 3 mmHg, respectively. Both experiments confirm chronic stimulation of IL-6 by mineralocorticoids but show that it is transient. In addition, IL-6 was not required for mineralocorticoid hypertension. This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.

Indexed as

Blood PressureAldosteroneAngiotensinsAnimalsAntihypertensive AgentsDesoxycorticosteroneDisease Models, AnimalHypertensionInfusion Pumps, ImplantableInfusions, SubcutaneousInterleukin-6MaleMiceMice, Inbred C57BLMice, KnockoutMineralocorticoid Receptor AntagonistsAldosteroneAngiotensinsAntihypertensive AgentsDesoxycorticosteroneInterleukin-6Mineralocorticoid Receptor AntagonistsSpironolactone

Identifiers

PMID19812355
PMCPMC2803630
OpenAlexW2096693144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.